Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models.

Ganesh S, Shui X, Craig KP, Koser ML, Chopda GR, Cyr WA, Lai C, Dudek H, Wang W, Brown BD, Abrams MT.

Mol Cancer Ther. 2018 Feb;17(2):544-553. doi: 10.1158/1535-7163.MCT-17-0605. Epub 2017 Dec 27.

PMID:
29282298
2.

Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Ganesh S, Koser ML, Cyr WA, Chopda GR, Tao J, Shui X, Ying B, Chen D, Pandya P, Chipumuro E, Siddiquee Z, Craig K, Lai C, Dudek H, Monga SP, Wang W, Brown BD, Abrams MT.

Mol Cancer Ther. 2016 Sep;15(9):2143-54. doi: 10.1158/1535-7163.MCT-16-0309. Epub 2016 Jul 7.

3.

Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.

Dutta C, Avitahl-Curtis N, Pursell N, Larsson Cohen M, Holmes B, Diwanji R, Zhou W, Apponi L, Koser M, Ying B, Chen D, Shui X, Saxena U, Cyr WA, Shah A, Nazef N, Wang W, Abrams M, Dudek H, Salido E, Brown BD, Lai C.

Mol Ther. 2016 Apr;24(4):770-8. doi: 10.1038/mt.2016.4. Epub 2016 Jan 13.

4.

Knockdown of β-catenin with dicer-substrate siRNAs reduces liver tumor burden in vivo.

Dudek H, Wong DH, Arvan R, Shah A, Wortham K, Ying B, Diwanji R, Zhou W, Holmes B, Yang H, Cyr WA, Zhou Y, Shah A, Farkiwala R, Lee M, Li Y, Rettig GR, Collingwood MA, Basu SK, Behlke MA, Brown BD.

Mol Ther. 2014 Jan;22(1):92-101. doi: 10.1038/mt.2013.233. Epub 2013 Oct 3.

Supplemental Content

Support Center